Knight Announces Canadian Regulatory Approval for ILUVIEN Via: https://globenewswire.com/news-release/2018/11/26/1656949/0/en/Knight-Therapeutics-Announces-Canadian-Regulatory-Approval-for-ILUVIEN.html
Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, today announced that Health Canada has approved ILUVIEN® for the treatment of diabetic macular edema (DME). ILUVIEN is a fluocinolone acetonide sustained release non-biodegradable intravitreal implant used to treat DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. Knight entered into an exclusive Canadian agreement for ILUVIEN with Alimera Sciences, Inc. (“Alimera”) in July 2015.
“The approval of ILUVIEN is great news for Canadian DME patients, payors and healthcare providers. ILUVIEN represents a well-studied, proven effective treatment for DME patients who can benefit from CONTINUOUS MICRODOSING without the burden of frequent injections,” said Jonathan Ross Goodman, CEO of Knight. “We are eager to work with all payors and stakeholders across Canada to make ILUVIEN available to Canadian patients.”
“We are excited that ILUVIEN has received approval by Health Canada,” said Dan Myers, CEO of Alimera. “ILUVIEN is the only treatment approved in Canada with CONTINUOUS MICRODOSING that can treat DME every day for up to three years with a single implant. We look forward to working with Knight to make ILUVIEN available to Canadian patients.”